BeiGene, Ltd. (“BeiGene”) is a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer.
BeiGene has a broad portfolio consisting of six internally-developed, clinical-stage, drug candidates, including three late-stage clinical drug candidates, zanubrutinib (BTK inhibitor), tislelizu...more >
|Stock Quote||more >|
03/26/19 4:00 p.m. ET
Currency is USD
Data provided by Nasdaq. Minimum 15 minutes delayed.
|Recent Press Releases||more >|
|Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics - March 6, 2019|
|Ambrx to receive an upfront payment of US$10 million to apply its proprietary Expanded Genetic Code platforms to discove... Read More|
|BeiGene to Present at Upcoming Investor Conferences - March 4, 2019|
|CAMBRIDGE, Mass., and BEIJING, China, March 04, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a ... Read More|